Lafuente A, Pujol F, Carretero P, Villa J P, Cuchi A
Institut de Salut Pública, Universitat de Barcelona, Spain.
Cancer Lett. 1993 Jan 15;68(1):49-54. doi: 10.1016/0304-3835(93)90218-x.
The isoenzyme mu of glutathione S-transferase (GST mu) is dominantly inherited and the prevalence of this isoenzyme in the population is about 60%. An increased risk of lung cancer has been previously shown among smokers lacking GST mu in (Seidegard J., Pero R.W., Miller D.G., Beattie E.J. (1986) Carcinogenesis, 7, 751-753). The frequency of the phenotypes of this isoenzyme in bladder cancer patients (n = 75), in larynx cancer patients (n = 78) and healthy controls matched for age and smoking history is reported here. A significantly higher proportion of smokers in the control group had measurable GST mu compared with bladder cancer patients (54.6% vs. 33.3%, P < 0.01) and also compared to larynx cancer patients (55.1% vs. 33.3%, P < 0.01). Odds ratio analysis indicates that smokers with this polymorphic variant have an approximately 2-fold greater risk of developing these cancers.
谷胱甘肽S-转移酶（GSTμ）的同工酶μ呈显性遗传，该同工酶在人群中的患病率约为60%。先前的研究表明，缺乏GSTμ的吸烟者患肺癌的风险增加（Seidegard J.、Pero R.W.、Miller D.G.、Beattie E.J.（1986年），《癌变》，7，751 - 753）。本文报告了该同工酶在膀胱癌患者（n = 75）、喉癌患者（n = 78）以及年龄和吸烟史相匹配的健康对照者中的表型频率。与膀胱癌患者相比，对照组中可检测到GSTμ的吸烟者比例显著更高（54.6%对33.3%，P < 0.01），与喉癌患者相比也是如此（55.1%对33.3%，P < 0.01）。优势比分析表明，具有这种多态性变体的吸烟者患这些癌症的风险大约高2倍。
